ArticleClinical kidney journal2022
Peritoneal dialysis-first initiative in India: a cost-effectiveness analysis.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Factors Influencing Telehealth Service Use and Health Outcomes in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Cross-Sectional Study.Journal of medical Internet research · 2023Trial
- Uncertainty in Economic Evaluation: A Pragmatic Guide for Health Technology Assessment (HTA) Agencies in Resource-Constrained Settings.PharmacoEconomics · 2026Review
- Cumulative blood pressure exposure and cognition: the potential mediating role of brain volume.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Strengthening kidney care through evidence-informed participatory policymaking.Nature reviews. Nephrology · 2026Article
- A cost- effectiveness and resource requirement comparison to optimize renal dialysis policies in Brunei Darussalam.Communications medicine · 2025Article
- Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.Nature reviews. Nephrology · 2025Review
- The burden of chronic kidney disease in Asia region: a review of the evidence, current challenges, and future directions.Kidney research and clinical practice · 2025Article
- Optimizing dialysis modalities for diabetic end-stage kidney disease: A focus on personalized care and resource-limited settings.World journal of diabetes · 2025Article
- International equity in access to home dialysis.Current opinion in nephrology and hypertension · 2025Review
- Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.Applied health economics and health policy · 2024Article
- Capacity for the management of kidney failure in the International Society of Nephrology South Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).Kidney international supplements · 2024Review
- Landscape of kidney replacement therapy provision in low- and lower-middle income countries: A multinational study from the ISN-GKHA.PLOS global public health · 2024Article
- Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model.BMC research notes · 2022Article
- Should More Patients with Kidney Failure Bring Treatment Home? What We Have Learned from COVID-19.Kidney diseases (Basel, Switzerland) · 2022Review
- The Influence of Hemodialysis on Ocular Pressure Dynamics: An Observational Study on IOP and OPP Changes.Journal of current glaucoma practiceArticle
- Increased Uptake of Peritoneal Dialysis after Inclusion of Peritoneal Dialysis in Mukhyamantri Vishesh Swasthya Sahayata Yojana in Chhattisgarh.Indian journal of nephrologyArticle
- Peritoneal Dialysis in India is Dying-Is Weaning from the Ventilator Likely?Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing burden of kidney failure (KF) in India necessitates provision of cost-effective kidney replacement therapy (KRT). We assessed the comparative cost-effectiveness of initiating KRT with peritoneal dialysis (PD) or haemodialysis (HD) in the Indian context.
methodsThe cost and clinical effectiveness of starting KRT with either PD or HD were measured in terms of life years (LYs) and quality-adjusted life years (QALYs) using a mathematical Markov model. Complications such as peritonitis, vascular access-related complications and blood-borne infections were considered. Health system costs, out-of-pocket expenditures borne by patients and indirect costs were included. Two scenarios were considered: Scenario 1 (real-world scenario)-as per the current cost and utilization patterns; Scenario 2 (public programme scenario)-use in the public sector as per Pradhan Mantri National Dialysis Programme (PMNDP) guidelines. The lifetime costs and health outcomes among KF patients were assessed.
resultsThe mean QALYs lived per KF person with PD and HD were estimated to be 3.3 and 1.6, respectively. From a societal perspective, a PD-first policy is cost-saving as compared with an HD-first policy in both Scenarios 1 and 2. If only the costs directly attributable to patient care (direct costs) are considered, the PD-first treatment policy is estimated to be cost-effective only if the price of PD consumables can be brought down to INR70/U.
conclusionsPD as initial treatment is a cost-saving option for management of KF in India as compared with HD first. The government should negotiate the price of PD consumables under the PMNDP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.